This company has been acquired
Salud financiera de hoja de balance de Sigilon Therapeutics
Salud financiera controles de criterios 5/6
Sigilon Therapeutics has a total shareholder equity of $27.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $55.6M and $28.1M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$34.90m |
| Patrimonio | US$27.45m |
| Total pasivo | US$28.11m |
| Activos totales | US$55.56m |
Actualizaciones recientes sobre salud financiera
Recent updates
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet
Apr 17
Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M
Aug 04Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer
Jun 14What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?
Mar 04Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.
Dec 17Análisis de la situación financiera
Pasivos a corto plazo: SGTX's short term assets ($44.9M) exceed its short term liabilities ($25.2M).
Pasivo a largo plazo: SGTX's short term assets ($44.9M) exceed its long term liabilities ($2.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: SGTX is debt free.
Reducción de la deuda: SGTX had no debt 5 years ago.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: SGTX has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: SGTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.6% each year